Background
==========

Hepatocellular carcinoma (HCC), the major histological subtype of primary liver cancer, is the third leading cause of cancer death worldwide \[[@B1]-[@B3]\]. In 2008, an estimated 749,000 people were diagnosed with liver cancer and 695,000 people died from it worldwide. The Asia-Pacific region accounted for approximately 75% of known new cases and deaths \[[@B3],[@B4]\]. Hence, controlling liver cancer in Asia is especially important for reducing its global burden.

Most Asian governments have implemented policies and laws to prevent Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infection, seeking to control HCC by targeting important risk factors. Universal hepatitis B vaccination, the most effective method to prevent Hepatitis B \[[@B5]\], has been implemented in the majority of Asian countries \[[@B6]\]. Top-down management of medical settings, especially blood centers and blood banks, also ensures the safety of blood products and reduces blood-transmitted HBV and HCV infection \[[@B7]\]. Meanwhile, screening programs for HBV infection, HCV infection and HCC have also been implemented in various ways. Routine HBsAg and anti-HCV tests are offered to voluntary blood donors in all Asian countries, and antenatal exams are offered in most countries \[[@B6]\]. Periodic hepatitis testing among high risk populations is conducted through national programs in Japan, South Korea and Taiwan \[[@B6],[@B8]-[@B10]\]. Public education campaigns in most countries also play a major role in increasing the public's and physicians' awareness of hepatitis and liver cancer \[[@B6],[@B11]\].

Although the above strategies help to reduce the spread of hepatitis to a large extent, HCC incidence and mortality rates are still increasing in Asia, mainly due to the long natural history from hepatitis to HCC, and the large existing population of HBV and HCV carriers \[[@B12]\]. Strategic national health plans specific to HCC control are needed, but there is a paucity of literature devoted to the optimal design of comprehensive liver cancer control (CLCC).

The WHO provides some guidance for the creation of comprehensive cancer control programs that can offer some guidance for the creation of a CLCC \[[@B13]\]. Similar targeted comprehensive cancer control plans have been advocated and programs implemented for breast, cervical, and colorectal cancer cancer \[[@B14]-[@B16]\]. To successfully implement CLCC, plans should reflect current needs \[[@B17],[@B18]\] and incorporate the views of a wide array of stakeholders \[[@B13]\].

The objective of this study was to identify priorities among multiple strategies for CLCC. Specifically we engaged stakeholders involved in clinical, policy, and advocacy activities related to CLCC in China, Japan, South Korea and Taiwan to document priorities and to test if they were concordant across the region and the stakeholder groups. These results are of interest to health care professionals and regulators in Asia, as well as their counterparts in other countries as they can contribute to national or regional efforts to implement CLCC. Our contribution is also important to a wider audience as it demonstrates a transparent and theoretically grounded approach to involving stakeholders in priority setting \[[@B19]\].

Priority setting methods
------------------------

If resources were unlimited, international and national decision-makers could immediately adopt all available CLCC strategies that could be expected to have an impact based on existing evidence \[[@B20]-[@B26]\]. Implementation is limited by a range of political, financial, human resource and time constraints, such that possible strategies have to be prioritized even if it is envisioned that all strategies will eventually be adopted \[[@B27],[@B28]\].

Cost-effectiveness analysis (CEA) provides one way to set priorities that focuses on allocating resources to where they are (potentially) most beneficial \[[@B29]\]. CEA has been criticized for inadequately incorporating the view of stakeholders \[[@B30]\], ignoring many costs and benefits that fall outside the health sector \[[@B31]\], and inaccurately assessing the benefits of programs \[[@B32]\]. Furthermore, as a decision-making tool, it requires a great deal of information about the costs and effects of programs which may not be available and often lacks transparency \[[@B33]\].

Other processes exist to study priorities that are less restrictive than CEA and, more importantly, allow for a more transparent participation of stakeholders in decision making. Traditionally deliberative process approaches have been used that rely upon qualitative methods \[[@B34]\] and Delphi approaches \[[@B35],[@B36]\]. While such approaches have an important role, they are grounded in normative political theory, rather than some explicit theory of prioritization \[[@B37]\]. Furthermore, the results of such analyses can be subject to the biases of the researchers or facilitators \[[@B38]\], by dominant respondents \[[@B39]\] or misinterpretation \[[@B40]\]. While modern approaches to deliberation, such as citizen juries \[[@B41]\] or Analytic Hierarchy Process (AHP) \[[@B42]\] have overcome some of these concerns, they are also more focused on decision making rather than the scientific study of priorities that may inform decision makers.

While simple rating and ranking approaches can be applied to priority setting exercises, they are subject to a range of biases and complexities \[[@B43]\]. The self-explicated methods, which combine ratings and rankings in a multiplicative way in an attempt to minimize the biases of rating and ranking alone, is one method that has potential for priority setting, especially in the presence of a large number of factors \[[@B17],[@B18],[@B44]\].

Stated-preference methods, such as conjoint analysis \[[@B45],[@B46]\] and best-worst scaling (BWS) \[[@B47]\], offer a potentially superior alternative to simple rating and ranking methods as they ensure people have to make tradeoffs \[[@B43]\]. Furthermore, as these methods can utilize random utility theory (RUT), they are more consistent with economic \[[@B48]\] and psychological \[[@B49]\] theories of choice.

In conjoint analysis, the factors that are to be assessed (which we might call objects to differentiate them from attributes that may vary across defined levels) are presented in competing subsets (traditionally two) and respondents are asked to make some judgment or choice as to which of the sets are better \[[@B50]\]. The benefit of this approach is that it reinforces the notion that multiple objects are likely to incorporated in the eventual policy. The downfall of this approach is that experimental designs used to create such subsets are often based on orthogonal or D-efficient designs that will lead to unbalanced numbers of objects in each subset \[[@B50]\]. Furthermore, such designs are generally "main-effects" which implies that key interactions between the objects are not estimated. Hence, one could not determine if objects were considered complements or substitutes in the minds of respondents.

In BWS case 1, which is known as the object case \[[@B51]\], respondents are presented with subsets of the objects and asked which subset is the best (with regards to some criteria such as "which will have the greatest effect?") and which is worst on those same criteria. The primary benefit of this approach is that it is a relatively easy decision that is relatable to real life situations. Researchers often use a balanced incomplete block design (BIBD) which ensures that there are the same number of objects in each task (at the cost of orthogonality) \[[@B51],[@B52]\]. The limitations of this method are that it enforces the notion that one of the objects is the best (rather than promoting that a portfolio of objects may be optimal) and that, like conjoint analysis, interactions are rarely explored.

Methods
=======

Stakeholders are often consulted during policy processes because they can provide critical insight overlooked by more objective evaluation methods \[[@B53]\]. The WHO recommended that policy makers incorporate stakeholders' input as part of a systematic and transparent evaluation of priorities \[[@B19]\]. For the purpose of this study we have chosen conjoint analysis as a means of involving stakeholders in the prioritization of strategies that could be incorporated into a CLCC plan. While this approach has limitations, as detailed above, we thought it important to reinforce the notion that a CLCC plan needed to incorporate multiple strategies.

In a previously published pilot study on this topic, the conjoint analysis approach was shown to be both feasible and functional even in a very low sample size (n=20) \[[@B54]\]. Several limitations of the original study were identified and were corrected in this present application of the technique. First, only a single stakeholder group (clinicians) was included; here we also have engaged both policy makers and advocates. Second, while a sample size of 20 was sufficient to measure aggregate priorities, we have aimed to examine heterogeneity across sites in Asia or across different stakeholder subgroups. Third, based on the pilot results, and comparison with qualitative data, several modifications to the survey instrument were recommended in the previous publication \[[@B54]\] and all have been incorporated here. Finally, the previous publication used publication guidelines designed for qualitative research, and not specifically targeted for conjoint analysis. While other guidelines for conjoint analysis have been proposed \[[@B55]-[@B58]\], this paper has adhered to recently published guidelines for the application of conjoint analysis in health care presented by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) \[[@B59]\].

Research question, perspective and rationale
--------------------------------------------

The primary research question was to identify stakeholder priorities across multiple strategies for CLCC in Asia, to assess if these differed across clinical, policy, and advocacy stakeholders and to explore the concordance of priorities across China, Japan, South Korea and Taiwan. Respondents were asked to use their own perspective in judging which strategies were better for their country. As discussed above, conjoint analysis was chosen as it is a valid method for assessing priorities and preference heterogeneity, and as it reinforced the notion that multiple strategies were needed if a CLCC were to be successful. No priors were used for the purpose of experimental design, and the hypotheses were centered on identifying which factors were deemed valuable and whether differences in priorities could be identified across stakeholders or countries.

Selection of CLCC strategies
----------------------------

Data from previous qualitative interviews (n=20) with international liver cancer clinicians were analyzed using Interpretive Phenomenological Analysis to identify these strategies \[[@B54]\]. A pilot was then conducted with clinicians from China, Japan, and Korea to assess the importance of these strategies in comparison with the qualitative data \[[@B54]\]. Based on this analysis, the wording of the strategies surfaced as a potential limitation of the pilot study. In order to avoid any ambiguity in interpretation in the present study, the strategy "Measuring the social burden of liver cancer" was relabeled "Measuring incidence, prevalence and burden of liver cancer" and the strategy "Improved risk-assessment and referral by primary care" was relabeled "Early risk assessment in primary care". An explanation of the eleven strategies presented in this conjoint analysis is presented in Table [1](#T1){ref-type="table"}.

###### 

Attributes included in the study

  **Label**                        **Strategy**                                                       **Description**
  -------------------------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Access to treatments             Improved access to recommended treatments                          All liver cancer patients and people that are at-risk of liver cancer have access to recommended medical care, including doctors' ability to request screening and tests for liver function and asymptomatic disease through liver cancer prevention and treatment, paid by governmental and/or private health insurance.
  Centers of excellence            Centers of excellence for liver cancer                             Referral of patients with liver cancer and other liver diseases that increase risk of liver cancer, to medical centers or research institutions with major liver disease departments that treat liver cancer and/or conduct the latest research in liver cancer. Specialized liver cancer centers to provide coordinated surveillance, treatment and research within a national liver cancer program.
  Clinician Education              Education of primary care physicians and hepatologists about HCC   Education of related healthcare providers (primary care physicians, internists, gastroenterologists, hepatologists) about liver cancer, such as the importance of early risk assessment, management of hepatic diseases to prevent progression to liver cancer.
  Measuring social burden          Measuring incidence, prevalence and burden of liver cancer         Measuring the health care costs or burden to the society, compared to screening, earlier detection and management of liver cancer patients or at-risk people.
  Monitoring at-risk population    Continuous surveillance of at-risk populations                     Monitoring at-risk populations to detect liver diseases and liver cancer at an early stage, including the stratification of disease risk and hepatic disease surveillance in those at high risk of HCC.
  Multidisciplinary management     Multidisciplinary management of HCC                                Due to the complex nature of liver cancer and multiple contributing factors, a highly skilled multidisciplinary team approach is necessary for managing liver cancer surgically and non-surgically, as well as managing patients with hepatitis and other diseases that significantly increase the risk of developing liver cancer.
  National guidelines              National standards and guidelines                                  The establishment and maintenance of nationwide, evidence-based standards and guidelines for the adoption of prevention, treatment and surveillance of liver cancer.
  Public awareness                 Organized disease advocacy and public awareness                    Widespread public awareness of risk factors and prevention for liver disease as well as liver cancer in the general population, including organized consumer liver disease and liver cancer advocacy.
  Research infrastructure          Increased infrastructure for translational research                Increased infrastructure, including capacity and qualified personnel, to conduct translational, clinical and basic research in all stages of liver cancer, from prevention to end-stage disease treatment and care.
  Risk Assessment and referral     Early risk assessment in primary care                              Earlier and improved risk assessment and screening by primary healthcare providers (general practitioners, internists, gastroenterologists) and immediate referral of patients with diagnosed liver disease and/or liver cancer to medical experts specializing in hepatic diseases and /or HCC.
  Transplantation infrastructure   Transplantation infrastructure and allocation                      Improved transplantation infrastructure and allocation of livers, including total liver transplants as well as partial transplants from living donors; sufficient highly skilled surgical and other healthcare providers, latest transplant techniques and technology.

Construction of choice tasks
----------------------------

These eleven strategies, which were considered as being present or absent in a potential plan, were assigned to one of two plans within each of the conjoint analysis choice tasks by creating two mutually exclusive and exhaustive subsets. This ensured all eleven strategies appear at least once in each choice task, but not twice. While there is some emerging evidence that triplets have some benefits over paired choice tasks \[[@B60]\], the use of pairs is currently the standard for applications in health \[[@B61]\]. As no country has adopted CLCC we did not incorporate a status quo into the choice tasks. An example of a choice task is illustrated in Figure [1](#F1){ref-type="fig"}.

![**An example of a conjoint analysis choice task** .](1472-6963-12-376-1){#F1}

Experimental design
-------------------

A main-effects orthogonal experimental design was used to create the choice tasks \[[@B62]\]. This ensured zero collinearity among strategies and that importance of each strategy could be estimated independently. This 2\^11 design involved eleven columns of binary numbers, one for each strategy, and twelve rows, which were translated into the twelve conjoint-analysis choice tasks presented in the survey. Here a strategy was placed on the left in a task if the orthogonal array indicated a zero and on the right if the orthogonal array indicated a one. Alternative strategies were also considered, including designs based on D-optimality and D-efficiency \[[@B59]\], but these approaches would have led to identical designs under the same assumptions. The properties of the experimental design were assessed, confirming that the design was orthogonal (both in terms of profiles and tasks), 100% D-Optimal for main effects in a paired experiment, and that level balance and zero overlap were achieved. Finally, with a design leading to only 12 choice tasks, the respondent burden was deemed acceptable based on experience with the pilot study and given current standards \[[@B59],[@B61]\].

Preferences elicitation and survey design
-----------------------------------------

In each of the 12 choice tasks, stakeholders were asked to choose the CLCC plan that they believed would have a more significant impact in their country. As such, a forced-choice preference elicitation procedure was used that is consistent with the underlying theory \[[@B48],[@B49]\]. Respondents were not asked to justify or explain their preferred strategy, and for simplicity strength of preference or confidence in their answer was not explored.

Prior to preference elicitation, respondents were provided sufficient motivation about the strategies to facilitate an appropriate response. An example choice task was also presented to confirm all respondents understood how to complete the choice tasks correctly.

The questionnaire also collected background information including respondents' areas of involvement and level of involvement in liver cancer control. The properties of the questionnaire were examined during the pilot study and relevant modifications were noted above.

Sampling strategy, ethical considerations and data collection
-------------------------------------------------------------

Based on the experience from our pilot, a sample of 20 respondents per country was used or n=80 overall. Although this is relatively small for a conjoint analysis \[[@B61]\], we had to acknowledge that relevant experts in liver cancer are not in endless supply. A strategy of purposive quota sampling was used to ensure that a relative balance of stakeholder types was recruited.

Clinical, policy, and advocacy stakeholders were purposively selected equally from China, Japan, South Korea and Taiwan. Potential respondents were actively involved in liver cancer prevention and control activities as identified by authoritative literature, medical and public health networks, peer referral and leadership roles in government agencies, national centers or medical institutes/associations. Study inclusion and exclusion criteria are shown in Table [2](#T2){ref-type="table"}. Exclusion criteria ensured all potential respondents were familiar with national liver cancer control policy and practice.
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Inclusion and exclusion criteria

  **Role**   **Inclusion criteria**                                                                                                                                                                                                                                                                                                                                          **Exclusion criteria**
  ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical   Oncologists, surgeons, radiologists, other HCC and hepatobiliary specialists, hepatologists, pathologists, and other specialists who may be involved in HCC prevention, diagnosis, treatment and care, or leaders of major medical institutions (including cancer and other liver disease centers).                                                             Not board certified, certified for less than one year, practicing medicine for less than 3 years, living/practicing in country for less than 3 years.
  Policy     Individuals in government, NGOs or other agencies involved in public education, awareness and prevention related to liver disease and liver cancer; national formularies and reimbursement decision-making; the development of policy and/or guidelines for the control of liver cancer; or those involved in policy related to liver transplantation.          Less than 1 year's experience in liver cancer and related fields; those not directly involved in policies impacting liver cancer prevention and control; or those with primary responsibilities as (and who otherwise primarily identify themselves as liver cancer) clinicians, advocates or in non-policy related roles.
  Advocacy   Recognized by liver cancer patients, physicians or policy leaders for their national advocacy role; significant consumer/patient advocacy of liver disease; leadership role in a nationally recognized advocacy group; evidence of an active media and/or publication history that is targeted to reach liver cancer patient or at-risk consumer populations.   Those with primary responsibilities as clinicians or in non-advocacy related roles; those whose scope of advocacy is limited to local environs, i.e. with little/no national impact or recognition by peers, clinical and policy leaders.

All respondents were informed about the study and its potential risks and benefits. Respondents participated voluntarily and were not reimbursed for participation. The study was deemed exempt from the Institutional Review Board (IRB) review at Johns Hopkins Bloomberg School of Public Health.

### Data collection

Potential respondents were contacted for participation via email or mail. Follow-up phone calls were made to those who did not respond within two weeks. If there was still no response after a maximum of four reminders, they were considered as "no response". Eligible respondents were invited to complete the survey by email or telephone. The survey was administered as an interviewer-assisted face-to-face interview in English and in the respondents' native languages where necessary between October 2010 and April 2011.

Statistical analysis, inference and validity
--------------------------------------------

Our data were structured so that an observation was obtained for each of the 12 tasks across the 80 respondents, leading to 960 observations (e.g. 12x80). The primary outcome (dependent variable) in the analysis was the liver cancer control plan selected by the participant for each task. Here each choice was coded as 1 if the respondent chose the plan on the left or 0 if they choose the plan on the right. The independent variables were a set of eleven dichotomous variables indicating which tasks were present. A strategy was coded as 1 if it was presented in the plan on the left and −1 if it was presented in the plan on the right. The coding strategy is required (as opposed to a traditional dichotomous variable) because the absence of the strategy on the left meant that it was automatically on the right. This can be seen in a linear representation of the underlying theory \[[@B48]\].

The difference in the value placed on the options (say *A* and *B*) can be expressed as simply subtraction between the value placed on the attributes presented in *A* and *B* respectively (denoted *X*^*A*^ and *X*^*B*^), as presented in eq. 1.

$$\Delta V = V\left( X^{A} \right) - V\left( X^{B} \right)$$

Given that we have assumed linearity and have eleven independent variables, we can think of the differences between the values as being defined as:

$$\Delta V = {\sum\limits_{i = 1}^{11}\beta_{i}}X_{i}^{A} - {\sum\limits_{i - 1}^{11}{\beta_{i}X_{i}^{B}}}$$

As *ΔV* is unobserved, we need a mechanism to approximate it. As seen in eq. 3, our dichotomous variable indicating which card was shown can approximate this difference and be regressed against difference in the cards using ordinary least squares. The restricted regression model is thus:

$$Y = \alpha + {\sum\limits_{i - 1}^{11}\beta_{i}}\left( {X_{i}^{A} - X_{i}^{B}} \right)$$

Regressing the respondents' choices on the strategies produced a set of coefficients for the strategies which will lead to the estimation of the *β*~*i*~, which will assess the marginal valuation of each of the eleven strategies. These estimated coefficients therefore showed the relative importance of different strategies in a hypothetical liver cancer control plan. The higher the value of the coefficients, the higher the strategy was prioritized. Coefficients with positive signs indicated the strategies were valued, while negative signs indicated respondents were opposed to those strategies.

To account for variation across our sample, say by country, we can stratify the model by allowing the *β* to vary by strategy *i* and country *j*, leading to:

$$Y = \alpha + {\sum\limits_{j = 1}^{4}{\sum\limits_{i - 1}^{11}\beta_{\mathit{ij}}}}\left( {X_{i}^{A} - X_{i}^{B}} \right) + \mathit{\varepsilon}$$

Here we chose not to consider differences in the constant term across the strata, as there was not theoretical reason to suggest that the strata were particularly biased to choose one side of the experiment over the other.

From eq. 4, differences across countries for each strategy are tested by applying restricted least squares (RLS) \[[@B63]\], using the *β*~*i*1~ = *β*~*i*2~ = *β*~*i*3~ = *β*~*i*4~ restriction, where the RLS will produce a Wald statistic that tests the significance of this restriction, and the overall test of differences across countries is conducted by testing all restrictions on the eleven strategies at once. The same model specification and Wald tests were used for the model stratified by stakeholder type.

Using the RLS based on ordinary least squares (OLS) estimates has a number of advantages over alternative strategies. First, OLS does not require the assumption of independence of irrelevant alternatives \[[@B48]\]. Second, the difference between logit and OLS is generally found to be small in conjoint analysis experiments \[[@B55],[@B64]\]. Third, given our main-effects orthogonal design and zero priors on parameters, a linear model can be considered more appropriate \[[@B64]-[@B66]\].

Robust standard errors were estimated to account for the clustering of multiple observations from each respondent. Analyses were conducted using Stata 11.2 for Windows (StataCorp LP, College Station, TX). The t-test and Wald test were used to test for significance and concordance respectively. Pearson Chi-Square tests were used to test for differences in stakeholder characteristics across the region. All the parameter estimates are multiplied by 100 to aid interpretation.

Results
=======

Eighty respondents were eligible and completed the survey (69.6% completion rate). As shown in Figure [2](#F2){ref-type="fig"}, 115 potential participants were invited to participate in the study. Of these, 19 (16.5%) did not respond, 7 (6.1%) refused to participate, 7 (6.1%) did not meet the inclusion criteria and 2 (1.7%) did not complete the survey.

![**Study recruitment** .](1472-6963-12-376-2){#F2}

Table [3](#T3){ref-type="table"} shows stakeholders' characteristics. Their primary roles were clinical (60%), policy (25%) and advocacy (15%). Their main areas of involvement were hepatitis (26.3%), hepatocellular carcinoma (57.5%), metastatic liver cancer (10.0%), and transplantation (6.3%). Respondents were involved in liver cancer control at international (15.0%), local/municipality (6.3%), national (56.3%) and regional/provincial (22.5%) levels.

###### 

**Characteristics of respondents** (**n**=**80**) **stratified by site**

                                 **All**   **China**   **Japan**   **South Korea**   **Taiwan**   **p**-**value**
  ----------------------------- --------- ----------- ----------- ----------------- ------------ -----------------
  **Primary Role**, %                                                                            
  ***Clinicians***                60.0       15.0        15.0           15.0            15.0           0.196
  Hepatologist                    18.8        2.5         5.0            7.5            3.8               
  Oncologist                      21.3       10.0         2.5            1.3            7.5               
  Radiologist                      3.8        1.3         1.3            1.3            0.0               
  Surgeon                         12.5        0.0         8.3            4.2            0.0               
  Other                            3.8        0.4         1.1            1.1            1.1               
  ***Policy makers***             25.0        6.3         6.3            6.3            6.3            0.167
  Governmental                    18.8        5.0         6.3            5.0            2.5               
  Non-Governmental                 6.3        1.3         0.0            1.3            3.8               
  ***Advocates***                 15.0        3.8         3.8            3.8            3.8            0.518
  Disease advocacy                 5.0        0.0         1.3            1.3            2.5               
  Media/Spokesperson               3.8        1.3         1.3            0.0            1.3               
  Patient advocacy                 6.3        2.5         1.3            2.5            0.0               
  **Area of Involvement**, %                                                                         0.002\*\*
  Hepatitis                       26.3        5.0        11.3            3.8            6.3               
  HCC                             57.5       17.5        13.7           16.3            10.0              
  Metastatic liver cancer         10.0        2.5         0.0            0.0            7.5               
  Transplantation                  6.3        0.0         0.0            5.0            1.3               
  **Level of Involvement**, %                                                                         0.029\*
  International                   15.0        3.8         3.8            5.0            2.5               
  Local/municipality               6.3        5.0         0.0            1.3            0.0               
  National                        56.3       13.7        11.3           17.5            13.7              
  Regional/provincial             22.5        2.5        10.0            1.3            8.8               

*\*p\<0.05, \*\*p\<0.01*.

In the aggregate analysis, all eleven strategies were positively valued and statistically significant (at p\<0.01) except for *transplantation infrastructure*. The most preferred strategy was *monitoring at-risk populations* (coefficient=13.75). The next preferred strategy was *clinician education* (11.04), followed by *national guidelines* (8.96), *multidisciplinary management* (8.33), *public awareness* (8.13), *centers of excellence* (6.86), *risk assessment* (5.42), *access to treatments* (5.21), *measuring social burden* (5.21), and research infrastructure (3.96). The coefficient for *transplantation infrastructure* (0.42) was not significantly different from zero (p=0.848), indicating it was not expected to have a significant impact. The constant term was not significantly different from 0.5 (50.2; p=0.866), indicating no bias towards plans on the left or the right.

In the subset analysis, we stratified the priorities by sites and stakeholder groups, as shown in Table [4](#T4){ref-type="table"} and Table [5](#T5){ref-type="table"}. Priorities differed across countries (p\<0.001). In China, *national guidelines* (14.17; p\<0.001) was valued highest and *transplantation infrastructure* was valued lowest (−8.33; p=0.025), as shown in Table [4](#T4){ref-type="table"}. In Japan and South Korea, *monitoring at-risk populations* (16.67 and 17.08 respectively; both p\<0.001) was identified as the top priority, but their least preferred strategies diverged: in Japan, *risk assessment* was valued lowest (0.83; p=0.732) while *transplantation infrastructure* was the lowest in South Korea (−0.42; p=0.877). In Taiwan, *measuring social burden* (12.92; p\<0.001) was valued highest and *research infrastructure* was valued lowest (1.25; p=0.677).

###### 

Priorities stratified by site

  **Variable**                      **Aggregate**    **China**     **Japan**    **South Korea**   **Taiwan**    **Chi-squaredp**-**value**
  -------------------------------- --------------- ------------- ------------- ----------------- ------------- ----------------------------
  Monitoring at-risk populations     13.75\*\*\*     9.17\*\*     16.67\*\*\*     17.08\*\*\*     12.08\*\*\*              0.20
                                        (1.5)          (3.1)         (2.7)           (3.3)           (2.5)                   
  Risk Assessment                    5.42\*\*\*       5.83\*         0.83           7.08\*         7.92\*\*                0.18
                                        (1.3)          (2.4)         (2.4)           (2.9)           (2.4)                   
  Access to treatments               5.21\*\*\*     10.83\*\*\*     5.83\*           1.25            2.92                  0.11
                                        (1.4)          (3.0)         (2.4)           (2.7)           (3.2)                   
  National guidelines                8.96\*\*\*     14.17\*\*\*   10.00\*\*\*      7.92\*\*          3.75                 0.02\*
                                        (1.4)          (2.8)         (3.3)           (2.7)           (2.0)                   
  Research infrastructure             3.96\*\*         4.17         6.67\*           3.75            1.25                  0.63
                                        (1.4)          (2.5)         (2.8)           (2.5)           \(3\)                   
  Centers of excellence              6.86\*\*\*       5.83\*      10.00\*\*\*       6.25\*          5.42\*                 0.60
                                        (1.5)          (3.9)         (2.5)           (1.9)           (3.1)                   
  Multidisciplinary management       8.33\*\*\*      7.50\*\*     11.67\*\*\*       6.25\*         7.92\*\*                0.44
                                        (1.4)          (2.4)         (2.1)           (3.4)           (2.7)                   
  Clinician education                11.04\*\*\*     7.50\*\*     10.83\*\*\*     15.42\*\*\*     10.42\*\*\*              0.15
                                        (1.3)          (2.3)         (3.2)           (2.5)           (2.6)                   
  Public awareness                   8.13\*\*\*        3.33         6.67\*        11.25\*\*\*     11.25\*\*\*              0.11
                                        (1.4)          (2.7)         (2.8)           (2.7)           (2.6)                   
  Transplantation infrastructure        0.42           −8.33         5.83            −0.42           4.58                0.01\*\*
                                        (1.5)          (3.6)         (2.4)           (2.7)           (2.7)                   
  Measuring Social Burden            5.21\*\*\*        2.50          2.50            2.92         12.92\*\*\*             0.04\*
                                        (1.4)          (2.5)         (2.7)           (2.4)           (3.1)                   

*\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, aggregate model R*^*2*^*=0.269, p\<0.001, stratified model R*^*2*^*=.320.*
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Priorities stratified by stakeholder role

  **Variable**                      **Aggregate**   **Clinicians**   **Policy Makers**   **Advocates**   **Chi-squaredp**-**value**
  -------------------------------- --------------- ---------------- ------------------- --------------- ----------------------------
  Monitoring at-risk populations     13.75\*\*\*     14.76\*\*\*        14.58\*\*\*         8.33\*                  0.28
                                        (1.5)           (2.0)              (2.6)             (3.6)                    
  Risk Assessment                    5.42\*\*\*        5.73\*\*            2.92             8.33\*                  0.47
                                        (1.3)           (1.6)              (2.7)             (3.6)                    
  Access to treatments               5.21\*\*\*         4.34\*            6.25\*             6.94                   0.76
                                        (1.4)           (1.7)              (3.6)             (3.6)                    
  National guidelines                8.96\*\*\*       9.55\*\*\*          7.08\*           9.72\*\*                 0.79
                                        (1.4)           (1.7)              (3.3)             (3.6)                    
  Research infrastructure             3.96\*\*         5.03\*\*            −1.25            8.33\*                  0.08
                                        (1.4)           (1.6)              (2.9)             (3.3)                    
  Centers of excellence              6.86\*\*\*       7.81\*\*\*           4.58              6.94                   0.66
                                        (1.5)           (1.9)              (3.0)             (3.9)                    
  Multidisciplinary management       8.33\*\*\*       9.20\*\*\*         7.92\*\*            5.56                   0.52
                                        (1.4)           (2.0)              (2.3)             (2.5)                    
  Clinician education                11.04\*\*\*     11.28\*\*\*         8.75\*\*         13.89\*\*\*               0.35
                                        (1.3)           (1.9)              (2.4)             (2.5)                    
  Public awareness                   8.13\*\*\*       9.20\*\*\*           3.75            11.11\*\*                0.15
                                        (1.4)           (1.8)              (2.5)             (3.8)                    
  Transplantation infrastructure        0.42             1.56              −2.92             1.39                   0.47
                                        (1.5)           (2.1)              (3.1)             (3.6)                    
  Measuring social burden            5.21\*\*\*          3.3             8.75\*\*            6.94                   0.25
                                        (1.4)           (1.6)              (3.0)             (4.8)                    

*\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, model R*^*2*^*=.287*.

Table [5](#T5){ref-type="table"} compares the results among stakeholder groups. Priorities differed across stakeholder groups (p=0.001). *Monitoring at-risk populations* was most preferred by clinical and policy stakeholders (14.76 and 14.58 respectively; both p\<0.001), while advocates valued *clinician education* (13.89; p\<0.001) highest. When it came to least preferred strategy, all stakeholder groups agreed on *transplantation infrastructure* (1.56, -2.92, and 1.39 for clinical, policy and advocacy stakeholders respectively; all p\>0.05).

As there were slight differences among groups, we tested for concordance across sites and stakeholder groups. Most priorities were concordant across sites except for three strategies: *transplantation infrastructure* (p=0.009) was valued lower in China than Japan (−8.33 vs 5.83; p=0.002) and Taiwan (−8.33 vs 4.58; p=0.006); *measuring social burden* (p=0.037) was valued significantly higher in Taiwan than in China, Japan and Taiwan (12.92 vs 2.5, 2.5, and 2.92 respectively; all p\<0.05); and *national guidelines* (p=0.025) with higher valuations in China than Taiwan (14.17 vs 3.75; p=0.003). In contrast, priorities were concordant across stakeholder groups with no differences for any of the strategies (all p\>0.05).

Discussion
==========

Strategies viewed as having the highest priority in Asia were *monitoring at-risk populations*, *clinician education*, *national guidelines*, *multidisciplinary management*, *public awareness, and centers of excellence.* Priorities were relatively concordant among the three groups of stakeholders (clinical, policy, and advocacy) and across the region. This said, three strategies, *transplantation infrastructure, measuring social burden*, and *national guidelines* received different priorities across the region. The fact that most priorities are shared across the four study sites provides justification for utilizing these strategies in the sites we studied, and suggests the findings could be generalized to other Asian countries with similar situations.

The strategy of *monitoring at-risk populations* is ranked as the top priority, consistent with some existing actions. Three of the four sites already have monitoring systems in place, suggesting either that the existing system is valued and should continue in a new comprehensive liver cancer control plan, or that the existing system could be improved. South Korea, Japan and Taiwan started national cancer screening programs in the 1990s with liver cancer screening as an important component \[[@B8],[@B10],[@B67]\]. Especially in Japan, where HCV infection is a major etiological cause of liver cancer, a HCV screening program has been implemented since the late 1980s \[[@B10]\]. Japan's National Project against Hepatitis and HCC specifically focuses on screening hepatitis carriers to prevent them from developing liver cancer and also to detect early-stage liver cancer patients \[[@B10]\]. Screening is an effective method to control liver cancer and improve prognosis, and might be expected to be one of the most important strategies for liver cancer control given the large existing populations of HBV and HCV carriers in most Asian countries \[[@B9]\].

The finding of heterogeneity in transplantation infrastructure across sites is interesting. Respondents from China valued this strategy extremely low, compared to those from the other three sites. This phenomenon is consistent with evidence of barriers to liver transplantation in China. Although demand for liver transplantation has been growing rapidly in China, ethical criteria and governing legislation have not yet been fully established, which deters the utilization of liver transplantation in liver cancer management \[[@B32],[@B33]\]. Without legislation, the quality and safety of liver transplantation are not supervised and guaranteed for patients who undergo surgery, and the legal rights of healthcare providers are not protected \[[@B68],[@B69]\]. Faults in the regulatory system also leave space for illegal organ trades \[[@B68]\]. In addition, liver cancer transplantation is an expensive surgical procedure that is not covered by health care insurance in China, so affordability is another barrier to full utilization \[[@B69]\]. Thus, it is reasonable that stakeholders from China did not consider it a high priority despite the fact that it is considered an effective treatment for some liver cancer patients.

Our study demonstrated that conjoint analysis, a stated preference method, can be utilized to prioritize strategies for a comprehensive disease control plan. It combines qualitative research methods with quantitative methods, and provides a comprehensive way to explore stakeholders' judgments in the policy decision-making process. Compared to CEA, the most prevalent prioritization tool in health economics, conjoint analysis has several advantages \[[@B31]\]. First, it can take into consideration all possible outcomes (including risks and costs) of health policies rather than just using a single measurement to rank them \[[@B31]\]. Conjoint analysis can integrate preferences from different stakeholders whose views are important when considering policy interventions, hence the results are a useful step towards developing consensus. Indeed, our study found good consensus among stakeholders from clinical, policy, and patient advocacy roles, who together should have a good understanding of decision making throughout their health systems. Second, the theoretical basis of conjoint analysis is less controversial than CEA, making it easier to justify the method to stakeholders such as physicians and policy makers \[[@B31]\].

This study demonstrated the usefulness of the conjoint-analysis method in studying stakeholders\' priorities for CLCC strategies, although there are a number of limitations that need to be considered. First, given that the data come from subjective responses, there might be some variations in preference due to respondents' specific positions, geography, or experience that do not truly reflect societal preferences and cannot be assessed with such a small sample. We tested concordance across the three selected stakeholder groups, and the results showed there was no statistically significant heterogeneity. However, to ensure representativeness and validity, additional important stakeholders should be included in future studies, such as patients and health policy researchers, and larger samples should be considered in countries such as China where there may be large differences in disease burden and resources within the country. In addition, if the sample size permitted, it would be useful to incorporate a latent class analysis in order to identify sources of heterogeneity that may not be captured by the characteristics that we chose to investigate.

A second limitation is that our study was conducted in countries where English is not the native language. Although the questionnaire was provided in both English and respondents' first languages, there might be some misunderstandings due to translation.

The third limitation is that the generalizability of the study is limited by the study sites that were selected. Among our four sites, Japan, South Korea and Taiwan are high-income countries, while China is different in terms of health care resources, health financing and people's socio-economic status. As most Asian countries are low or middle income countries, the results may not be applicable to all Asian countries. Further studies could be conducted in low or middle income parts of Asia to examine whether strategies are prioritized differently in such areas.

A fourth limitation of using conjoint analysis to assess priorities is that respondents may have simply preferred plans with more strategies than others. While all strategies were positively correlated with the number of strategies, this was uniform across the strategies, so bias in the prioritization would be difficult. This said, we did re-estimate the aggregate model by holding constant the number of attributes (which also required dropping the intercept to avoid the dummy variable trap). We did identify that there was a significant effect associated with the number of strategies presented in the model (p\<0.001). In correcting for this bias, we found that only five strategies were significantly different to zero and positive (*monitoring at-risk populations*: 9.2, p\<0.001; *clinician education*: 6.5, p\<0.001; *national guidelines*: 4.4, p=0.003; *multidisciplinary management*: 3.8, p=0.008; and *public awareness*: 3.6, p=0.011) and one was statistically significant and negative (*transplantation infrastructure*: -4.1, p=0.011). In comparing these results to those reported above, the exact prioritization across the strategies was estimated. Future research is needed on separating the number of objects in a conjoint from the marginal effects estimated for each parameter.

Finally, the study sample size remains low and may lack generalizability to other Asian countries. The robustness of the results obtained in the aggregate model and the stratified models confirm the findings of the pilot study that small sample sizes can be used \[[@B54]\]. This said, the lack of statistical difference between the groups can be attributed to the low sample size. While simulation techniques may provide some benefit in overcoming low sample sizes, such methods would also have to correct for the underlying differences in scale that may be present across the strata.

Conclusions
===========

This study has used a systematic and transparent method to produce a prioritization of effective strategies for liver cancer control in Asia. The finding of concordance across four sites, despite differences in liver cancer etiology and resources across sites, suggests that the priorities are applicable to other parts of the region. The results of this study constitute a ready-to-use, prioritized plan for liver cancer control based on the views of key stakeholders. The next step is for decision makers to implement the priority strategies as comprehensive national plans and to instigate cross-national or regional collaborations that can use the similarities in priorities to improve liver cancer control across the region.
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